A treatment mainstay for prostate cancer puts men at increased risk for diabetes and cardiovascular disease, according to a large observational study published in the// Sept. 20 Journal of Clinical Oncology.
“Men with prostate cancer have high five-year survival rates, but they also have higher rates of non-cancer mortality than healthy men,” says study author Nancy Keating, MD, MPH, assistant professor of health care policy and of medicine at Harvard Medical School. “This study shows that a common hormonal treatment for prostate cancer may put men at significant risk for other serious diseases. Patients and physicians need to be aware of the elevated risk as they make treatment decisions.”
The principal systemic therapy for prostate cancer involves blocking testosterone production. This is done either by removal of the testes (bilateral orchiectomy), or more commonly, by regular injections of a gonadotropin-releasing hormone (GnRH) agonist drug. GnRH agonists are the main therapy for metastatic prostate cancer and may also improve survival for some men with locally-advanced cancers.
However, little is known about the efficacy of GnRH agonists in treating men with less-advanced local or regional prostate cancer, many of whom receive this therapy. Earlier studies have found GnRH agonists to be associated with obesity and insulin resistance, a precursor to diabetes.
“Our study found that men with local or regional prostate cancer receiving a GnRH agonist had a 44 percent higher risk of developing diabetes and a 16 percent higher risk of developing coronary heart disease than men who were not receiving hormone therapy,” says Keating, who is also a physician at Brigham and Women’s Hospital.
“Doctors should think twice about prescribing GnRH agonists in situations for which studies have not demonstrated improved survival until we better understand the risks of treatment,” says co-author Matthew Smith, MD, PhD, aPage: 1 2 Related medicine news :1
. Cancer Doctors Okays Controversial Prostate Therapy2
. Radioactive Seeds used in Prostate Cancer treatment can migrate with the body3
. New Prostate Cancer Vaccine Shows Promise4
. Hormone Therapy applicable for Prostate Cancer5
. Prostate cancer and Vitamins 6
. Response to chemotherapy could be measured by Prostate-Specific Antigen Doubling Time7
. Early Detection Of Prostate Cancer8
. Awareness increase Prostate cancer detection9
. Better Prostate Cancer Test10
. Stopping Prostate Cancer from Spreading11
. Drug might prevent Prostate Cancer Spread